These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32509782)

  • 1. The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice.
    Sharma AK; Roberts RL; Benson RD; Pierce JL; Yu K; Hamrick MW; McGee-Lawrence ME
    Front Cell Dev Biol; 2020; 8():354. PubMed ID: 32509782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells.
    Yang C; Qiao W; Xue Q; Goltzman D; Miao D; Dong Z
    J Orthop Translat; 2024 Nov; 49():107-118. PubMed ID: 39430127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Senolytic effects on dental pulp stem cell's proliferation and differentiation during long-term expansion].
    Wang GY; Liao L; Tian WD
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2024 May; 59(5):444-452. PubMed ID: 38636998
    [No Abstract]   [Full Text] [Related]  

  • 4. Navitoclax (ABT-263) Rejuvenates Human Skin by Eliminating Senescent Dermal Fibroblasts in a Mouse/Human Chimeric Model.
    Takaya K; Ishii T; Asou T; Kishi K
    Rejuvenation Res; 2023 Feb; 26(1):9-20. PubMed ID: 36324221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice.
    Fielder E; Wan T; Alimohammadiha G; Ishaq A; Low E; Weigand BM; Kelly G; Parker C; Griffin B; Jurk D; Korolchuk VI; von Zglinicki T; Miwa S
    Elife; 2022 May; 11():. PubMed ID: 35507395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Senescent Cells in the Bone Microenvironment.
    Farr JN; Fraser DG; Wang H; Jaehn K; Ogrodnik MB; Weivoda MM; Drake MT; Tchkonia T; LeBrasseur NK; Kirkland JL; Bonewald LF; Pignolo RJ; Monroe DG; Khosla S
    J Bone Miner Res; 2016 Nov; 31(11):1920-1929. PubMed ID: 27341653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
    González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
    Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteocytes regulate senescence of bone and bone marrow.
    Ding P; Gao C; Gao Y; Liu D; Li H; Xu J; Chen X; Huang Y; Zhang C; Zheng M; Gao J
    Elife; 2022 Oct; 11():. PubMed ID: 36305580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss.
    Chandra A; Lagnado AB; Farr JN; Monroe DG; Park S; Hachfeld C; Tchkonia T; Kirkland JL; Khosla S; Passos JF; Pignolo RJ
    J Bone Miner Res; 2020 Jun; 35(6):1119-1131. PubMed ID: 32023351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cellular senescence prevents age-related bone loss in mice.
    Farr JN; Xu M; Weivoda MM; Monroe DG; Fraser DG; Onken JL; Negley BA; Sfeir JG; Ogrodnik MB; Hachfeld CM; LeBrasseur NK; Drake MT; Pignolo RJ; Pirtskhalava T; Tchkonia T; Oursler MJ; Kirkland JL; Khosla S
    Nat Med; 2017 Sep; 23(9):1072-1079. PubMed ID: 28825716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of senolytic drugs on human mesenchymal stromal cells.
    Grezella C; Fernandez-Rebollo E; Franzen J; Ventura Ferreira MS; Beier F; Wagner W
    Stem Cell Res Ther; 2018 Apr; 9(1):108. PubMed ID: 29669575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells.
    Escriche-Navarro B; Garrido E; Sancenón F; García-Fernández A; Martínez-Máñez R
    Acta Biomater; 2024 Mar; 176():405-416. PubMed ID: 38185231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263/Navitoclax improves functional hyperemia in aged mice.
    Tarantini S; Balasubramanian P; Delfavero J; Csipo T; Yabluchanskiy A; Kiss T; Nyúl-Tóth Á; Mukli P; Toth P; Ahire C; Ungvari A; Benyo Z; Csiszar A; Ungvari Z
    Geroscience; 2021 Oct; 43(5):2427-2440. PubMed ID: 34427858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
    Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
    Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans.
    Farr JN; Rowsey JL; Eckhardt BA; Thicke BS; Fraser DG; Tchkonia T; Kirkland JL; Monroe DG; Khosla S
    J Bone Miner Res; 2019 Aug; 34(8):1407-1418. PubMed ID: 30913313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-cadherin/wnt interaction controls bone marrow mesenchymal cell fate and bone mass during aging.
    Haÿ E; Dieudonné FX; Saidak Z; Marty C; Brun J; Da Nascimento S; Sonnet P; Marie PJ
    J Cell Physiol; 2014 Nov; 229(11):1765-75. PubMed ID: 24664975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular Senescence: A Translational Perspective.
    Kirkland JL; Tchkonia T
    EBioMedicine; 2017 Jul; 21():21-28. PubMed ID: 28416161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous mutation of Dock7 results in lower trabecular bone mass and impaired periosteal expansion in aged female Misty mice.
    Le PT; Bishop KA; Maridas DE; Motyl KJ; Brooks DJ; Nagano K; Baron R; Bouxsein ML; Rosen CJ
    Bone; 2017 Dec; 105():103-114. PubMed ID: 28821457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer.
    Estepa-Fernández A; García-Fernández A; Lérida-Viso A; Blandez JF; Galiana I; Sancenon-Galarza F; Orzáez M; Martínez-Máñez R
    Pharmacol Res; 2023 Jan; 187():106628. PubMed ID: 36566002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone-targeted delivery of senolytics to eliminate senescent cells increases bone formation in senile osteoporosis.
    Xing X; Tang Q; Zou J; Huang H; Yang J; Gao X; Xu X; Ma S; Li M; Liang C; Tan L; Liao L; Tian W
    Acta Biomater; 2023 Feb; 157():352-366. PubMed ID: 36470392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.